Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical is poised to see significant growth due to recent societal guidelines addressing occupational radiation exposure that make the case for its LIBERTY robotic system stronger. With a proven track record of operator and ergonomic benefits, adoption of LIBERTY is expected to accelerate as operators gain experience using the system. This, coupled with decreasing costs of revenue and international expansion, is expected to lead to margin inflection in 2027 and a competitive advantage in the market. Recent adoption of LIBERTY by Emory Healthcare and strong financial results for 2025 suggest a positive outlook for the company in the future.

Bears say

Microbot Medical is facing significant near-term challenges as their expected adoption has been slower than anticipated, while their monthly cash burn is expected to significantly increase. Additionally, the company's system-level VAC approvals have not been as widespread as initially anticipated, leading to a longer ramp-up period and lower long-term revenue expectations. These factors contribute to the analyst's negative outlook on Microbot Medical's stock.

Microbot Medical (MBOT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.